secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2022-12-12T23:59:59+00:00
Accession:  0001213900-22-078840
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences shareholders approve reverse stock split authorization and elect directors
--------------------------------------------------------------------------------

- All five director nominees elected; Yutaka Niihara, MD received 23.2M votes for.
- Approved amendment to authorize reverse stock split at ratio between 1:5 and 1:8 within one year.
- Ratification of Baker Tilly as independent auditor for fiscal 2022 approved with 29.5M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/0001213900-22-078840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390022078840/ea169928-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-078840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer